Why the CSL Limited share price is looking up

Shares in biotechnology company CSL Limited (ASX: CSL) hit a new record high of $145.62 in Thursday’s trading session despite no announcement being released to the market.

CSL shares have soared 45% over the past 12 months after the Melbourne-based company continues to deliver excellent profit growth on the back of strong demand for its immunoglobulin and specialty products in conjunction with rising margins.

The company’s shares have now risen 14% after announcing its FY 17 numbers in mid August where it posted a net profit of $US1,337 million on a constant currency basis – a 24% improvement on 2016.

Future growth

CSL is not resting on its laurels either, with the company cancelling its successful share buyback program to redistribute its free cash flow towards an extensive capex program of between $US900 million and $US1 billion in FY 2018.

The capex program is geared towards enhancing the company’s growth prospects with substantial investments being planned to expand its fractionation capacity, increase the number of collection centres and boost manufacturing capacity for specialty products such as Haegarda and Berinert.

The acquisition of Chinese plasma fractionator Ruide should also contribute strongly to future earnings with the Chinese immunoglobulin market the fastest growing market in the world and a shortage predicted to occur over the next decade.

The influenza vaccine division Seqirus is also seeing revenue growth and is on the path to profitability.

Foolish takeaway

CSL remains one of the best Australian companies to profit from a depreciating Australian dollar with a considerable amount of its revenue derived in US dollars around the world.

The stock continues to be the star of the Australian healthcare sector and whilst far from cheap offers a more compelling valuation than fellow healthcare heavyweight Cochlear Limited (ASX: COH).

CSL has guided for FY 2018 net profit to rise between 11% to 16% at constant currency and trades at approximately 32x forward earnings. In contrast, Cochlear has guided for net profit to grow between 7% to 12% and trades at about 41 times forward earnings.

Why Elon Musk’s “secret weapon” was the most shorted share in Australia...

On 9 March, the visionary Tesla co-founder and CEO made a bold $63,000,000 to save a large swath of Australia. But in the process, he accidentally revealed the small Melbourne-based company that allows him to consistently make the impossible possible. At one point, this little understood company was actually the single most heavily shorted share in all of the ASX. Yet oddly enough, nine out of 10 analysts call it a screaming BUY! And that includes Motley Fool Australia.

We just isolated this company as Elon Musk’s “secret weapon”, and think it’s dynamic run (up more than double after initially floating shares just two and a half years ago!) is only getting started. For the full story on this company, as well as how to get invested alongside us today, simply click here!

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.